Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: A systematic review

BMC Health Services Research

Volumn 7, Issue , 2007, Pages

  Smeets, Hugo M ^a,b   Hoes, Arno W ^a   De Wit, Niek J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Agis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACID SUPPRESSIVE DRUG; ANTIULCER AGENT; UNCLASSIFIED DRUG; ANTACID AGENT; PROTON PUMP;

ARTICLE; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; EMBASE; HUMAN; MEDLINE; METHODOLOGY; PRESCRIPTION; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; DRUG UTILIZATION; DYSPEPSIA; ECONOMICS; GASTROESOPHAGEAL REFLUX; HEALTH CARE PLANNING; REVIEW; TREATMENT OUTCOME;

ANTACIDS; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HEALTH PLAN IMPLEMENTATION; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROTON PUMPS;

EID: 38349059867     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-7-177     Document Type: Article

References (50)

1. Chronic acid-suppressive drug use in Amsterdam in 2002. Agis Zorgverzekeringen, Amersfoort, Agis 2003
2. Farmacie in Cijfers: maagmiddelen. Stichting Farmaceutische Kengetallen, Pharmaceutisch Weekblad 2000 135 27
3. Van klacht naar diagnose. IM Okkes SK Oskam H Lamberts, Episodegegevens uit de huisartspraktijk Bussem, Coutinho 1998
4. Gebruik van maagmiddelen 1996-2001. GIP Signaal, Genees- en hulpmiddelen Informatie Project/College voor Zorgverzekeringen, Amstelveen 2002 nr.2
5. Trends and determinants of Pharmacotherapy for dyspepsia: analysis of 3-year prescription data in the Netherlands. AO Quartero HM Smeets NJ Wit de, Scand J Gastroenterol 2003 38 676 677 10.1080/00365520310001923 12825878
6. Multidisciplinaire Richtlijn Maagklachten. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Alphen aan de Rijn, Van Zuiden Communications 2003
7. Tweede nationale studie naar ziekten en verrichtingen in de huisartspraktijk. Klachten en aandoeningen in de bevolking en in de huisartspraktijk. MW Van Der Linden GP Westert DH De Bakker FG Schellevis, Utrecht, Nivel 2004
8. Review article: prevalence and epidemiology of gastro-oesophageal reflux disease. BC Delaney, Aliment Pharmacol Ther 2004 20 Suppl 8 2 4 10.1111/j.1365-2036.2004.02219.x 15575863
9. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. A Fraser B Delaney P Moayyedi, Am J Gastroenterol 2005 100 2 442 52 10.1111/j.1572-0241.2005.40122.x 15667506
10. Pharmacological interventions for non-ulcer dyspepsia (Cochrane review). S Soo P Moayyedi J Deeks B Delaney M Innes D Forman, The Cochrane Library Oxford:Updata 2000 2
11. What makes the dyspeptic patient feel ill? A cross sectional survey of functional health status, Helicobacter pylori infection, and psychological distress in dyspeptic patients in general practice. AO Quartero WMW Post ME Numans RA De Melker NJ De Wit, Gut 1999 45 15 19 10369698
12. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on demand' therapy for 6 months. NJ Talley K Lauritsen H Tunturi-Hihnala T Lind B Moum C Bang T Schulz TM Omland M Delle O Junghard, Aliment Pharmacol Ther 2001 15 347 54 10.1046/j.1365-2036.2001.00943.x 11207509
13. Initial management strategies for dyspepsia. B Delaney AC Ford D Forman P Moayyedi M Qume, Cochrane Database Syst Rev 2005 4 CD001961 16235292
14. Arrest of chronic acis suppressant drug use after successful H. Pylori eradication in patients with peptic ulcer disease: a six-month follow-up study. GJ Hurenkamp HG Grundmeijer A Van Der Ende GN Tytgat WJ Assendelft RW Van Der Hulst, Aliment Pharmacol Ther 2001 15 7 1047 54 10.1046/j.1365-2036.2001.01017.x 11421881
15. Drug treatment of functional dyspepsia. NJ Talley, Scand J Gastroenterol Suppl 1991 182 47 60 1896830
16. How do primary care physicians use long-term Acid suppressant drugs? A population-based analysis of Dutch general practices. GJB Hurenkamp HGLM Grundmeyer PJE Bindels GNJ Tytgat RWM Van Der Hulst, J Fam Pract 2002 51 241 45 11978235
17. Rapport Twee markten verkent. Experimentele ontmanteling GVS en loslating WTG-vergoedingssystematiek: maagmiddelen en cholesterolverlagers. College voor Zorgverzekeringen, Amstelveen, CVZ 2002
18. Quality of life in upper gastrointestinal disorders. I Wilhelmsen, Scand J Gastroenterol Suppl 1995 211 21 25 10.3109/00365529509090288 8545625
19. Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. HJ O'Connor, Aliment Pharmacol Ther 2002 16 3 487 96 10.1046/j.1365-2036.2002.01183.x 11876702
20. Management issues in dyspepsia: current consensus and controversies. NJ Talley N Vakil B Delaney B Marshall P Bytzer L Engstrand W de Boer R Jones P Malfertheiner L Agreus, Scand J Gastroenterol 2004 39 10 913 8 10.1080/00365520410003452 15513327
21. Effect of implementation of a dyspepsia and Helicobacter pylori eradication guideline in primary care. Fabrizio Cardin Manuel Zorzi Emanuela Bovo Cosimo Guerra Fabio Bandini Daniele Polito Francesca Bano Anna Maria Grion Roberto Toffanin, Digestion 2005 72 1 1 7 Epub 2005 Jul 25 10.1159/000087215 16088146
22. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. LA Bero R Grilli JM Grimshaw E Harvey AD Oxman MA Thomson, BMJ 1998 317 465 468 9703533
23. Changing provider behavior: an overview of systematic reviews of interventions. JM Grimshaw L Shirran R Thomas G Mowatt C Fraser L Bero, Med Care 2001 39 8 Suppl 2 II2 45 11583120
24. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. R Grol J Dalhuijsen S Thomas C In't Veld G Rutten H Mokking, BMJ 1998 317 858 61 9748183
25. Problems with implementing guidelines: a randomised controlled trial of consensus management of dyspepsia. RH Jones S Lydeard J Dunleavey, Quality in Health Care 1993 2 217 21 10132454
26. Audit and feedback: effects on professional practice and health care outcomes. G Jamtvedt JM Young DT Kristoffersen MA O'Brien AD Oxman, Cochrane Database Syst Rev 2006 2 CD000259 16625533
27. Educational outreach visits: effects on professional practice and health care outcomes. M O'brien S Rogers G Jamtvedt A Oxman J Odgaard-Jensen D Kristoffersen L Forsetlund D Bainbridge N Freemantle DA Davis R Haynes E Harvey, Cochrane Database Syst Rev 2007 4 CD000409 17943742
28. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. B Shaw F Cheater R Baker C Gillies H Hearnshaw S Flottorp N Robertson, Cochrane Database Syst Rev 2005 3 CD005470 16034980
29. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. J Jailwala TF Imperial K Kroenke, Ann Intern Med 133 2 136 47 2000 Jul 18 10896640
30. Guidelines on appropriate indications for upper gastrointestinal endoscopy. Working Party of the Joint Committee of the Royal College of Physicians of London, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons, the British Society of Gastroenterology, and the thoracic Society of Great Britain. AT Axon GD Bell RH Jones MA Quine RF McCloy, BMJ 310 6983 853 6 1995 Apr 1 7711627
31. Guidelines for dyspepsia management in general practice using focus groups. AP Hungin GP Rubin AJ Russell B Convery, Br J Gen Pract 1997 47 418 275 9 9219401
32. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. SJO Veldhuyzen van Zanten N Flook N Chiba D Armstrong A Barkun M Bradette the Canadian Dyspepsia Working Group, CMAJ 162 12 Suppl s3 23 2000 June 13 10870511
33. Helicobacter pylori-related disease. Guidelines for Testing and Treatment. LP Walter M Fendrick DR Cve DA Peura SM Garabedian-Ruffalo L Laine, Arch Intern Med 2000 160 1285 91 10.1001/archinte.160.9.1285 10809031
34. Proton pump inhibitors. Compliance with a mandated step-up program. MM Mamdani K Tu L Jaakkimainen A Bica J Hux, Can Fam Physician 2001 47 531 5 11281086
35. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. G Manes A Balzano P Marone M Lionello S Mosca, Aliment Pharmacol Ther 2002 16 1 105 10 10.1046/j.1365-2036.2002.01136.x 11856084
36. Are dyspepsia management guidelines coherent with primary care practice? F Cardin M Zorzi A Furlanetto C Guerra F Bandini D Polito F Bano AM Grion R Toffani, Scand J Gastroenterol 2002 37 11 1269 75 10.1080/003655202761020533 12465724
37. Guidelines on the management of H. pylori in primary care: development of an implementation strategy. NJ De Wit J Mendive B Seifert F Cardin G Rubin, Fam Pract 2000 17 Suppl 2 s27 32 10.1093/fampra/17.suppl_2.S27 10960432
38. Noninvasive Helicobacter pylori testing for the 'test-and-treat' strategy: a decision analysis to access the effect of past infection on the test choice. WD Chey AM Fendrick, Arch Intern Med 161 17 2129 32 2001 Sep 24 10.1001/archinte.161.17.2129 11570943
39. Treating dyspepsia: new OTC drug changes the economic picture. No authors, Dis Manag Advis 2003 9 10 133 4 14679871
40. Appropriateness of indications for upper gastrointestinal endoscopy in open-access endoscopy units. A Sanchez-del Rio E Quintero O Alarcon, Gastroenterol Hepatol 2004 27 3 119 24 10.1157/13058395 14998463
41. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders. F Bursey M Crowley C Janes CJ Turner, CMAJ 162 6 817 23 2000 Mar 21 10750472
42. Outcomes of initial non-invasive Helicobacter pylori testing in U.S. primary care patients with uninvestigated dyspepsia. U Ladabaum AM Fendrick JM Scheiman, Am J Gastroenterol 2001 96 7 2051 7 10.1111/j.1572-0241.2001.03938.x 11467631
43. A novel approach for implementing evidence-based guidelines in the community: the Appropriate Choices in Dyspepsia project. D Chan P Patel L Booth D Lee ThHS Dent F Harris M Sadler H Shepherd, Journal of Clinical Excellence 2001 2 219 23
44. Tapering the use of chronic acid suppressant drugs in H. pylori negative chronic dyspeptic patients on maintenance therapy; an intervention strategy. GJ Hurenkamp HG Grundmeijer A Van Der Ende GN Tytgat WJ Assendelft RW Van Der Hulst, Thesis, Amsterdam 2001
45. Financial incentive versus education for implementation of a dyspepsia guideline: a randomised trial in primary care. CF Weijnen NJ De Wit M Wensing ME Numans TJM Verheij AW Hoes, Gastroenterol 2002 122 Suppl 1A 576 9
46. Salford and Trafford Ulcer Research Network. Modifying dyspepsia management in primary care: a cluster randomised controlled trial of educational outreach compared with passive guideline dissemination. G Banait B Sibbald D Thompson C Summerton M Hann S Talbot, Br J Gen Pract 2003 53 487 94 100 12817353
47. Problems with implementing guidelines: a randomised controlled trial of consensus management of dyspepsia. RH Jones S Lydeard J Dunleavey, Quality in Health Care 1993 2 217 21 10132454
48. A randomized controlled trial of Test-and-Treat strategy for Helicobacter pylori. JE Allison LB Hurley RA Hiatt ThR Levin LM Ackerson TA Lieu, Arch Intern Med 2003 163 1165 71 10.1001/archinte.163.10.1165 12767952
49. The effect of Helicobacter pylori treatment strategy on health care in patients with peptic ulcer disease and dyspepsia. DJ Kearney CF Liu C Crump A Brousal, Am J Gastroenterol 2003 98 1952 62 10.1111/j.1572-0241.2003.07584.x 14499771
50. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. N Krol M Wensing F Haaijer-Ruskamp JWM Muris ME Numans G Schattenberg J van Balen R Grol, Aliment Pharmacol Ther 19 8 917 22 2004 Apr 15 10.1111/j.1365-2036.2004.01928.x 15080853